Opinion: Why the FDA should not approve an ineffective multicancer screening test
There must be some mistake. A company studies its cancer blood test in a randomized trial of 140,000 people using a suboptimal surrogate endpoint, fails to meet that endpoint, yet is recommended for approval by a Food and Drug Administration…
ImpactMinor 11/100
Why it mattersRule-based estimate: event keywords (+4), soft/evergreen signals; trust 8/10.
RegionsGlobal
Published3 h ago (Tue, 06 Oct 2026 08:30:00 GMT)
RetrievedTue, 06 Oct 2026 11:00:28 GMT via rss
ClassifiedTue, 06 Oct 2026 11:00:35 GMT by heuristic
AuthorH. Gilbert Welch